Improved Glycemic Control in Intensively Treated Adult Subjects with Type 1 Diabetes Using Insulin Guidance Software
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Management of type 1 diabetes could be significantly improved with the availability of computerized insulin algorithms for home use. METHODS: This was a 1-year open label randomized control trial involving 123 adult subjects with type 1 diabetes (hemoglobin A1c values 7.5-11%) assigned to either the insulin guidance software (ACCU-CHEK) [Roche, Indianapolis, IN] Advisor) for personal data assistant (experimental group) or the control group. The primary aim of the study was to see if subjects using insulin dosing advisor software will improve glucose control over 1 year. The principal end point was an improvement in A1c at 6 and 12 months by >or=0.4%. RESULTS: Baseline demographics were similar in the two groups. Mean A1c was 8.54+/-0.11% in the control group and 8.42+/-0.11% (P=0.4265) in the experimental group. The mean A1c was significantly lower from 3 to 12 months in the experimental group (P<0.02). A1c reduction of >or=0.6% was maintained at 12 months in the experimental group. Also, a significantly higher number of subjects achieved A1c <7.5% in the experimental group from 3 to 9 months. Within target range glycemia (70-150 mg/dL) was higher in the experimental group at 3-9 months without any change in insulin dose or weight. Above target range glycemia was lower in the experimental group throughout the study. Frequency of testing per day was higher in the experimental group. Nocturnal hypoglycemia was not different between groups; however, the experimental group experienced more severe hypoglycemic events. CONCLUSIONS: This is the first report that shows improved glycemic control can be maintained over 12 months in patients with type 1 diabetes by using Advisor with no change in insulin dose and weight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth
Vehik, K., Hamman, R. F., Lezotte, D., Norris, J. M., Klingensmith, G., Bloch, C., Rewers, M., & Dabelea, D. (2007) · Diabetes Care · doi:10.2337/dc06-1837 · Cited by 226
Bailey, T. S., Zisser, H. C., & Garg, S. K. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0205 · Cited by 159
Self-citationChase, H. P., Saib, S. Z., MacKenzie, T., Hansen, M. M., & Garg, S. K. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00685.x · Cited by 116
Self-citation
Cited by
Continuous glucose monitoring systems for type 1 diabetes mellitus
Langendam, M., Luijf, Y. M., Hooft, L., DeVries, J. H., Mudde, A. H., & Scholten, R. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008101.pub2 · Cited by 262
Schmidt, S., & Nørgaard, K. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814532906 · Cited by 170
Optimized glycemic control of type 2 diabetes with reinforcement learning: a proof-of-concept trial
Wang, G., Liu, X., Ying, Z., Yang, G., Chen, Z., Liu, Z., Zhang, M., Yan, H., Lu, Y., Gao, Y., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02552-9 · Cited by 156
“WTR indicates the blood glucose value within the target range 3.9–10.0 mmol L −1 for each timepoint 5,26 .”
BackgroundInfluentialReddy, M., Pesl, P., Xenou, M., Toumazou, C., Johnston, D., Georgiou, P., Herrero, P., & Oliver, N. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0413 · Cited by 70
A novel pen-based Bluetooth-enabled insulin delivery system with insulin dose tracking and advice
Bailey, T. S., & Stone, J. Y. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1313831 · Cited by 60
Metadata
- Authors
- Garg, S. K., Bookout, T. R., McFann, K. K., Kelly, W. C., Beatson, C., Ellis, S. L., Gutin, R. S., & Gottlieb, P. A.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2008-10
- Volume
- 10
- Issue
- 5
- Pages
- 369-375
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2010796291
- Cited by
- 43
- References
- 4
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.